ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

40 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1Phase 2Idiopathic CD4 Lymphopenia

Recombinant human interleukin (IL) 7-hyFc

National Institute of Allergy and Infectious Diseases (NIAID)60 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Phase 2ImmunodeficiencyHematopoietic Stem Cell Transplantation

Allogeneic HSCTBusulfan test doseMycophenolate mofetil (MMF)+6 more

National Cancer Institute (NCI)54 participants1 site · United StatesCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants53 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants249 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 40

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

40 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1Phase 2Idiopathic CD4 Lymphopenia

Recombinant human interleukin (IL) 7-hyFc

National Institute of Allergy and Infectious Diseases (NIAID)60 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Phase 2ImmunodeficiencyHematopoietic Stem Cell Transplantation

Allogeneic HSCTBusulfan test doseMycophenolate mofetil (MMF)+6 more

National Cancer Institute (NCI)54 participants1 site · United StatesCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants53 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants249 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 40